Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1151555.RAMm8SZ5ecqqG43QjcCgq8UBVcKlSMllW8_ytU3WZHbZE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1151555.RAMm8SZ5ecqqG43QjcCgq8UBVcKlSMllW8_ytU3WZHbZE130_assertion type Assertion NP1151555.RAMm8SZ5ecqqG43QjcCgq8UBVcKlSMllW8_ytU3WZHbZE130_head.
- NP1151555.RAMm8SZ5ecqqG43QjcCgq8UBVcKlSMllW8_ytU3WZHbZE130_assertion description "[The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1151555.RAMm8SZ5ecqqG43QjcCgq8UBVcKlSMllW8_ytU3WZHbZE130_provenance.
- NP1151555.RAMm8SZ5ecqqG43QjcCgq8UBVcKlSMllW8_ytU3WZHbZE130_assertion evidence source_evidence_literature NP1151555.RAMm8SZ5ecqqG43QjcCgq8UBVcKlSMllW8_ytU3WZHbZE130_provenance.
- NP1151555.RAMm8SZ5ecqqG43QjcCgq8UBVcKlSMllW8_ytU3WZHbZE130_assertion SIO_000772 24490604 NP1151555.RAMm8SZ5ecqqG43QjcCgq8UBVcKlSMllW8_ytU3WZHbZE130_provenance.
- NP1151555.RAMm8SZ5ecqqG43QjcCgq8UBVcKlSMllW8_ytU3WZHbZE130_assertion wasDerivedFrom befree-2016 NP1151555.RAMm8SZ5ecqqG43QjcCgq8UBVcKlSMllW8_ytU3WZHbZE130_provenance.
- NP1151555.RAMm8SZ5ecqqG43QjcCgq8UBVcKlSMllW8_ytU3WZHbZE130_assertion wasGeneratedBy ECO_0000203 NP1151555.RAMm8SZ5ecqqG43QjcCgq8UBVcKlSMllW8_ytU3WZHbZE130_provenance.